




Newsletter - August 6, 2025

WE TAKE PRIDE IN OUR IP ENFORCEMENT!



Well Cell Global LLC and its affiliates have won a significant legal victory in the U.S. District Court for the Southern District of Texas. On May 14, 2025, Senior U.S. District Judge Lee H. Rosenthal entered a final judgment and permanent injunction awarding a total of \$16,771,973.71 in damages against defendants who violated Well Cell's intellectual property rights related to Well Cell Global's proprietary Physiologic Insulin Resensitization® technology.

Court Finds Willful and Malicious Violations

The federal court found that the defendants engaged in willful and malicious trade secret misappropriation, unfair competition, and trademark infringement after their licenses were revoked for improper use. The court further determined that the defendants continued to use Well Cell Global's proprietary medical training materials, specialized treatment protocols, and trademarks without authorization, causing significant harm to the company's business and reputation.

The court issued a permanent injunction prohibiting the defendants from:

- Using Well Cell Global's proprietary insulin resensitization method
- Disclosing trade secrets including confidential business contacts and specialized medical training
- Using Well Cell Global's trademarks or confusingly similar derivatives

The Court was quite thorough, and this is a direct quote from the Final Judgment, that defendants are prohibited from: ***“Using any of the knowledge, information, training, or materials taught, delivered, described, or otherwise imparted from Plaintiffs, in whole or in part, as part of any medical procedure, treatment, therapeutic modality, or otherwise.”***

Yesterday Well Cell issued a press release about the judgment, which also appears at www.wellcellglobal.com.

“This exemplifies the protection and support we provide for our licensees,” said Scott Hepford, CEO. “We will not tolerate infringement of our property we have fought so hard to secure for Well Cell and its licensees,” he added. Well Cell owns 3 patents related to PIR® and has 3 additional ones pending and is continuing to advance PIR with significant research and development efforts.

REMINDER: NextGen PIR is a recent advancement in Well Cell’s technology that will help with decreased infusion time for providers and patients, infusion cost reductions, and increased patient satisfaction! Well Cell will always be leading this field!



When you connect with us on social media, you get premium access to all kinds of new information from Well Cell!